404


Looks like the page you are trying to reach is no longer available.

Latest news

news
  • February 29th, 2024

From Images to Impact: Radiomics' Solutions to Challenges in Immunotherapy


Up to 30% of patients may experience hyper progression following immunotherapy. Identifying patients who will actually benefit from immunotherapy is intrinsic to achieving optimal outcomes. Radiomics can offer a solution to this problem by analysing the phenotypical changes in lesions and organs that may occur following the initiation of a treatment.

press
  • September 5th, 2023

Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients


Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients

press
  • April 7th, 2023

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy


DeuterOncology joins forces with Radiomics to develop a clinical tool to predict patient response to treatment.